One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Thrombotic and bleeding complications during antithrombotic treatment: the need for new therapeutic targets
Filippo Crea
doi : 10.1093/eurheartj/ehad285
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1767–1770
New director opens a fresh chapter in the history of a leading US heart centre
Judith Ozkan
doi : 10.1093/eurheartj/ehad138
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1771–1772
A memory for Claudio Rapezzi
Roberto Ferrari
doi : 10.1093/eurheartj/ehac773
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1773–1774
The physician and the monk
Ankur Kalra
doi : 10.1093/eurheartj/ehad037
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1775–1777
Higher hospital readmissions in blacks after acute myocardial infarction: healthcare inequality gaps to fill in secondary prevention
Daniela Pedicino, Massimo Volpe
doi : 10.1093/eurheartj/ehad179
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1778–1779
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding
Davide Cao, Nicolas Amabile, Mauro Chiarito, Victoria T Lee, Dominick J Angiolillo, Davide Capodanno, Deepak L Bhatt, Michael J Mack, Robert F Storey, Michael Schmoeckel, C Michael Gibson, Efthymios N Deliargyris, Roxana Mehran
doi : 10.1093/eurheartj/ehad119
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1780–1794
Remarkable progress has been made in the pharmacological management of patients with cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless, bleeding complications remain frequent and potentially life-threatening.
Reversal agents for current and forthcoming direct oral anticoagulants
Nick van Es, Raffaele De Caterina, Jeffrey I Weitz
doi : 10.1093/eurheartj/ehad123
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1795–1806
Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban.
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
Alexander P Benz, Stefan H Hohnloser, John W Eikelboom, Anthony P Carnicelli, Robert P Giugliano, Christopher B Granger, Josephine Harrington, Ziad Hijazi, David A Morrow, Manesh R Patel, David J Seiffge, Ashkan Shoamanesh, Lars Wallentin, Qilong Yi, Stuart J Connolly
doi : 10.1093/eurheartj/ehad200
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1807–1814
The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a stroke event while on oral anticoagulation.
Ischaemic stroke in atrial fibrillation patients while on oral anticoagulation—a call for A-C-T-I-O-N
Haeusler Karl Georg
doi : 10.1093/eurheartj/ehad203
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1815–1817
JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study
Luca Liberale, Yustina M Puspitasari, Stefano Ministrini, Alexander Akhmedov, Simon Kraler, Nicole R Bonetti, Georgia Beer, Ana Vukolic, Dario Bongiovanni, Jiaying Han, Kilian Kirmes, Isabell Bernlochner, Jaroslav Pelisek, Jürg H Beer, Zheng-Gen Jin, Daniela Pedicino, Giovanna Liuzzo, Konstantinos Stellos, Fabrizio Montecucco, Filippo Crea, Thomas F Lüscher, Giovanni G Camici
doi : 10.1093/eurheartj/ehac641
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1818–1833
Variants of the junctional cadherin 5 associated (JCAD) locus associate with acute coronary syndromes. JCAD promotes experimental atherosclerosis through the large tumor suppressor kinase 2 (LATS2)/Hippo pathway. This study investigates the role of JCAD in arterial thrombosis.
JCAD: a new GWAS target to reduce residual cardiovascular risk?
Tomasz J Guzik, Keith M Channon
doi : 10.1093/eurheartj/ehac708
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1834–1836
Thrombolytic treatment of life-threatening pulmonary embolism in times of alteplase shortage
Frederikus A Klok, Piotr Pruszczyk, Stavros V Konstantinides
doi : 10.1093/eurheartj/ehad120
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1837–1839
Closure of patent foramen ovale after surgery with atrial septal defect occluder accompanied by Marfan syndrome
Zhang Cheng, Junzhou Pu, Wenhui Wu
doi : 10.1093/eurheartj/ehad159
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Page 1840
Flow visualization of a unique case of persistent truncus arteriosus with prolonged survival
Yao Xie, Chengchen Zhao, Meixiang Xiang
doi : 10.1093/eurheartj/ehad183
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Page 1841
Cardiac Richter’s syndrome: a rare case of chronic lymphocytic leukaemia transformation
Eleonora Guarnieri, Vincenzo Castiglione, Raffaele De Caterina
doi : 10.1093/eurheartj/ehad184
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Page 1842
Corrigendum to: JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study
doi : 10.1093/eurheartj/ehad174
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Page 1843
Corrigendum to: Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection
doi : 10.1093/eurheartj/ehad167
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Pages 1844–1845
Erratum to: The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
doi : 10.1093/eurheartj/ehad090
European Heart Journal, Volume 44, Issue 20, 21 May 2023, Page 1806
